DTx Pharma Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
50
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.1B
DTx Pharma General Information
Description
Developer of RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company's therapeutics use a delivery technology platform that permits efficient delivery of nucleic acid drugs to tissues throughout the body that work in many cell types including neurons, endothelial, and T cells, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses.
Contact Information
Website
www.dtxpharma.comCorporate Office
- 10655 Sorrento Valley Road
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 10655 Sorrento Valley Road
- Suite 100
- San Diego, CA 92121
- United States
DTx Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 14-Jul-2023 | $1.1B | Completed | Generating Revenue | ||
| 8. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 7. Early Stage VC | 21-Mar-2021 | Completed | Generating Revenue | |||
| 6. Grant | 13-May-2020 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC (Series A) | 06-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 15-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 01-Jun-2018 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | 01-Dec-2017 | Completed | Startup |
DTx Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
DTx Pharma Comparisons
Industry
Financing
Details
DTx Pharma Competitors (3)
One of DTx Pharma’s 3 competitors is Arcturus Therapeutics Holdings, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Avidity Biosciences | Formerly VC-backed | San Diego, CA |
DTx Pharma Patents
DTx Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023091985-A1 | Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease | Inactive | 18-Nov-2021 | ||
| WO-2023086978-A2 | Branched triple lipid-modified nucleic acid compounds | Inactive | 15-Nov-2021 | ||
| WO-2023086978-A3 | Branched triple lipid-modified nucleic acid compounds | Inactive | 15-Nov-2021 | ||
| WO-2023086979-A1 | Staggered triple lipid-modified nucleic acid compounds | Inactive | 15-Nov-2021 | ||
| WO-2023049716-A1 | Compounds targeting nrl for the treatment of retinitis pigmentosa | Inactive | 21-Sep-2021 | C12N15/113 |
DTx Pharma Signals
DTx Pharma Former Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Alzheimer's Association | Corporation | |||
| Angel (individual) | Minority | |||
| CMT Research Foundation | Not-For-Profit Venture Capital | Minority | ||
| CONNECT (San Diego) | Accelerator/Incubator | Minority |
DTx Pharma FAQs
-
When was DTx Pharma founded?
DTx Pharma was founded in 2017.
-
Where is DTx Pharma headquartered?
DTx Pharma is headquartered in San Diego, CA.
-
What is the size of DTx Pharma?
DTx Pharma has 50 total employees.
-
What industry is DTx Pharma in?
DTx Pharma’s primary industry is Drug Delivery.
-
Is DTx Pharma a private or public company?
DTx Pharma is a Private company.
-
What is the current valuation of DTx Pharma?
The current valuation of DTx Pharma is .
-
What is DTx Pharma’s current revenue?
The current revenue for DTx Pharma is .
-
How much funding has DTx Pharma raised over time?
DTx Pharma has raised $112M.
-
Who are DTx Pharma’s investors?
Access Biotechnology, Alzheimer's Association, , CMT Research Foundation, and CONNECT (San Diego) are 5 of 34 investors who have invested in DTx Pharma.
-
Who are DTx Pharma’s competitors?
Arcturus Therapeutics Holdings, Alnylam Pharmaceuticals, and Avidity Biosciences are competitors of DTx Pharma.
-
When was DTx Pharma acquired?
DTx Pharma was acquired on 14-Jul-2023.
-
Who acquired DTx Pharma?
DTx Pharma was acquired by Novartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process